Physician profile
Mark A Mandelbaum
NPI 1629033428
$19,115.15
in general payments reported to CMS, 2019-2025
48 companies · $3,329 in 2025
The $3,329 reported for 2025 was more than what 80% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,577 · 2020: $9,137 · 2021: $2,472 · 2022: $709 · 2023: $344 · 2024: $1,546 · 2025: $3,329.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,788 · Education: $281 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,787.66 |
| Education | $281.49 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $10,096.33 | 2019-2021 | |
| Biogen, INC. | $787.88 | 2020-2025 | Vumerity, Tysabri, Skyclarys |
| Alexion Pharmaceuticals, INC. | $689.75 | 2019-2025 | Ultomiris |
| Lundbeck LLC | $669.54 | 2020-2025 | Vyepti |
| Novartis Pharmaceuticals Corporation | $653.81 | 2019-2024 | |
| Tg Therapeutics, INC. | $643.30 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $504.38 | 2019-2025 | Austedo Xr |
| Lilly USA, LLC | $485.72 | 2019-2025 | Kisunla, Emgality, Reyvow |
| Pfizer INC. | $419.88 | 2023-2025 | |
| Abbvie INC. | $350.93 | 2022-2025 | |
| Celgene Corporation | $319.60 | 2022-2025 | Zeposia |
| Ucb, INC. | $315.94 | 2020-2025 | Rystiggo, Nayzilam |
| Genzyme Corporation | $244.55 | 2019-2025 | |
| Acadia Pharmaceuticals INC | $217.62 | 2020-2025 | Nuplazid |
| Argenx US, INC. | $216.36 | 2024-2025 | Vyvgart, Vyvgart Hytrulo |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Mandelbaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.